Literature DB >> 28123579

miR-143 inhibits bladder cancer cell proliferation and enhances their sensitivity to gemcitabine by repressing IGF-1R signaling.

Hengbing Wang1, Qi Li2, Xiaobing Niu3, Gongcheng Wang3, Sinian Zheng3, Guangbo Fu3, Zengjun Wang4.   

Abstract

microRNAs (miRNAs) are a class of small RNAs that regulate gene expression. It has been demonstrated that aberrant miRNA expression is associated with cancer development and carcinogenesis. Altered miRNA expression has been suggested to occur in bladder cancer. In other cancer systems, studies have indicated that miR-143, as a tumor suppressor gene, plays essential roles in cancer progression. However, its role in bladder cancer has yet to be elucidated. In the present study, we observed that miR-143 expression was downregulated in human bladder cancer tissues and cells, and that its levels were negatively correlated with bladder cancer clinical stages. We further demonstrated that insulin-like growth factor-1 receptor (IGF-1R) is a functional target of miR-143. Their expression levels were inversely correlated in bladder cancer samples. Overexpression of miR-143 inhibited cell proliferation and promoted chemosensitivity of bladder cancer 5637 cells to gemcitabine. Consistently, small interfering RNA-mediated knockdown of IGF-1R phenocopied miR-143 overexpression. Notably, the expression of IGF-1R is a predictor of patient prognosis. Collectively, our findings indicate that miR-143 is a valuable biomarker for bladder cancer. The miR-143/IGF-1R axis is associated with bladder cancer drug resistance and patient survival.

Entities:  

Keywords:  IGF-1R; bladder cancer; gemcitabine; miR-143; tumor growth

Year:  2016        PMID: 28123579      PMCID: PMC5245146          DOI: 10.3892/ol.2016.5388

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Focus on bladder cancer.

Authors:  Colin P N Dinney; David J McConkey; Randall E Millikan; Xifeng Wu; Menashe Bar-Eli; Liana Adam; Ashish M Kamat; Arlene O Siefker-Radtke; Tomasz Tuziak; Anita L Sabichi; H Barton Grossman; William F Benedict; Bogdan Czerniak
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

Review 3.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

4.  FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Authors:  Adel H Jebar; Carolyn D Hurst; Darren C Tomlinson; Colin Johnston; Claire F Taylor; Margaret A Knowles
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

5.  MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells.

Authors:  Enders K O Ng; Rufina Li; Vivian Y Shin; Jennifer M Siu; Edmond S K Ma; Ava Kwong
Journal:  Tumour Biol       Date:  2013-11-13

Review 6.  Relevance of miR-21 in HIV and non-HIV-related lymphomas.

Authors:  Durairaj Sekar; Villianur Ibrahim Hairul Islam; Krishnaraj Thirugnanasambantham; Subramanian Saravanan
Journal:  Tumour Biol       Date:  2014-06-25

Review 7.  Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.

Authors:  D L Lamm; D R Riggs; C L Traynelis; U O Nseyo
Journal:  J Urol       Date:  1995-05       Impact factor: 7.450

8.  Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro.

Authors:  Lars Dyrskjøt; Marie S Ostenfeld; Jesper B Bramsen; Asli N Silahtaroglu; Philippe Lamy; Ramshanker Ramanathan; Niels Fristrup; Jens L Jensen; Claus L Andersen; Karsten Zieger; Sakari Kauppinen; Benedicte P Ulhøi; Jørgen Kjems; Michael Borre; Torben F Orntoft
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

9.  MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.

Authors:  Xu Qian; Jing Yu; Yu Yin; Jun He; Lin Wang; Qi Li; Lou-Qian Zhang; Chong-Yong Li; Zhu-Mei Shi; Qing Xu; Wei Li; Li-Hui Lai; Ling-Zhi Liu; Bing-Hua Jiang
Journal:  Cell Cycle       Date:  2013-04-08       Impact factor: 4.534

10.  Real-time quantification of microRNAs by stem-loop RT-PCR.

Authors:  Caifu Chen; Dana A Ridzon; Adam J Broomer; Zhaohui Zhou; Danny H Lee; Julie T Nguyen; Maura Barbisin; Nan Lan Xu; Vikram R Mahuvakar; Mark R Andersen; Kai Qin Lao; Kenneth J Livak; Karl J Guegler
Journal:  Nucleic Acids Res       Date:  2005-11-27       Impact factor: 16.971

View more
  22 in total

1.  miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.

Authors:  Jingyi Cao; Qichao Wang; Gang Wu; Shasha Li; Qian Wang
Journal:  Int Urol Nephrol       Date:  2018-08-16       Impact factor: 2.370

Review 2.  MicroRNAs: Key Players in Bladder Cancer.

Authors:  Qi Li; Helei Wang; Hourong Peng; Qiuping Huang; Ting Huyan; Qingsheng Huang; Hui Yang; Junling Shi
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

3.  Acarbose attenuates migration/proliferation via targeting microRNA-143 in vascular smooth muscle cells under diabetic conditions.

Authors:  Wei-Yuan Chuang; Meng-Hsun Yu; Tsung-Yuan Yang; Kuei-Chuan Chan; Chau-Jong Wang
Journal:  J Food Drug Anal       Date:  2020-09-15       Impact factor: 6.157

Review 4.  Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.

Authors:  Sen Liu; Xu Chen; Tianxin Lin
Journal:  J Adv Res       Date:  2021-11-24       Impact factor: 12.822

5.  Pharmacological Inhibition of miR-130 Family Suppresses Bladder Tumor Growth by Targeting Various Oncogenic Pathways via PTPN1.

Authors:  Yuya Monoe; Kentaro Jingushi; Akitaka Kawase; Takayuki Hirono; Ryo Hirose; Yoshino Nakatsuji; Kaori Kitae; Yuko Ueda; Hiroaki Hase; Yuichi Abe; Jun Adachi; Takeshi Tomonaga; Kazutake Tsujikawa
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

6.  Effects of microRNA-135a on the epithelial-mesenchymal transition, migration and invasion of bladder cancer cells by targeting GSK3β through the Wnt/β-catenin signaling pathway.

Authors:  Xia-Wa Mao; Jia-Quan Xiao; Zhong-Yi Li; Yi-Chun Zheng; Nan Zhang
Journal:  Exp Mol Med       Date:  2018-01-19       Impact factor: 8.718

Review 7.  Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.

Authors:  Cecilia Pop-Bica; Diana Gulei; Roxana Cojocneanu-Petric; Cornelia Braicu; Bogdan Petrut; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2017-07-13       Impact factor: 5.923

8.  MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy.

Authors:  Yalda Baghay Esfandyari; Mohammad Amin Doustvandi; Mohammad Amini; Behzad Baradaran; Sheyda Jodeiry Zaer; Nazila Mozammel; Mehdi Mohammadzadeh; Ahad Mokhtarzadeh
Journal:  Reprod Sci       Date:  2021-02-10       Impact factor: 3.060

9.  Biological Function of Ribosomal Protein L10 on Cell Behavior in Human Epithelial Ovarian Cancer.

Authors:  Jimin Shi; Lingyun Zhang; Daibing Zhou; Jinguo Zhang; Qunbo Lin; Wencai Guan; Jihong Zhang; Weimin Ren; Guoxiong Xu
Journal:  J Cancer       Date:  2018-02-06       Impact factor: 4.207

10.  The association of polymorphisms in miRNAs with nonsmall cell lung cancer in a Han Chinese population.

Authors:  Chuanyin Li; Yu Zhang; Yingfu Li; Qianli Ma; Shuyuan Liu; Yueting Yao; Fang Tan; Li Shi; Yufeng Yao
Journal:  Cancer Manag Res       Date:  2018-04-10       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.